Fort Sheridan Advisors LLC Crispr Therapeutics Ag Transaction History

Fort Sheridan Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$110.2 - $156.64 $201,555 - $286,494	-1,829 Closed	0 $0
Q2 2021 Aug 17, 2021	BUY	$100.84 - $161.89 $10,084 - $16,188	100 Added 5.78%	1,829 $296,000
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $30,115 - $57,130	272 Added 18.67%	1,729 $211,000
Q4 2020 Feb 16, 2021	BUY	$79.67 - $173.23 $116,079 - $252,396	1,457 New	1,457 $223,000

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.19B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Fort Sheridan Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Fort Sheridan Advisors LLC with notifications on news.